Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis

Figure 4

Tofacitinib inhibits inflammatory responses in the IMQ-induced psoriasiform mouse model. (a) Representative pictures of back-shaved mice left untreated (left), IMQ-treated (middle), or undergoing to cotreatment with IMQ and 10 mM tofacitinib. (b) Representative H&E staining of (i) untreated, (ii) treated with IMQ cream, and in the presence of 10 mM (iii) or 0.5 mM (iv) tofacitinib. Mouse skin treated with IMQ reverted their condition after tofacitinib topical application of 0.5 and 10 mM. The quantification of (c) epidermal, (d) scale thickness, and (e) cell infiltrate number was analysed as parameters of skin acanthosis and inflammation. Graphs show means of microns of epidermis and stratum corneum thickness and mean of number of cells infiltrating dermis per section, ±SD per group ( mice). .

(a)

(b)

(c)

(d)

(e)